Phio Pharmaceuticals

Seite 1 von 18
neuester Beitrag: 11.01.22 14:31
eröffnet am: 18.03.19 08:24 von: DA_BUA Anzahl Beiträge: 449
neuester Beitrag: 11.01.22 14:31 von: RichyBerlin Leser gesamt: 93687
davon Heute: 45
bewertet mit 3 Sternen

Seite: 1 | 2 | 3 | 4 |
16 | 17 | 18 | 18   

18.03.19 08:24
3

6084 Postings, 3711 Tage DA_BUAPhio Pharmaceuticals

Phio Pharmaceuticals
WKN: A2N9QM
ISIN: US71880W2044
US-Symbol: PHIO

Kurs:
https://www.nasdaq.com/de/symbol/phio/real-time

 
Seite: 1 | 2 | 3 | 4 |
16 | 17 | 18 | 18   
423 Postings ausgeblendet.

30.03.21 10:25

3251 Postings, 1496 Tage Claudimaltypischer sharesdeal chart loool

und da gabs ja schon ein split.oh man was für flachzangen.  

11.04.21 00:08
1

10244 Postings, 5034 Tage RichyBerlinPhio heute auf der AACR

PHIO PHARMACEUTICALS PRESENTS POSITIVE IN VIVO DATA SHOWING STRONG TUMOR CONTROL FOR THE INTRATUMORAL DELIVERY OF INTASYL RNAI TARGETING PD-1
Apr 10, 2021
Data presented at the AACR Annual Meeting 2021
https://investors.phiopharma.com/news-releases/...data-showing-strong


 

21.04.21 20:08
2

1421 Postings, 4336 Tage logall......

23.04.21 22:51

10244 Postings, 5034 Tage RichyBerlinPhio

Wenig Volumen.. Aber vielleicht doch der Kickstarter für eine Trendwende !?
 
Angehängte Grafik:
phio_2021-04-23.png (verkleinert auf 28%) vergrößern
phio_2021-04-23.png

24.04.21 02:21

10 Postings, 270 Tage MelaniejbcfaLöschung


Moderation
Zeitpunkt: 24.04.21 10:30
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

24.04.21 13:50

9 Postings, 270 Tage DianabhscaLöschung


Moderation
Zeitpunkt: 24.04.21 21:43
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: -

 

 

25.04.21 01:20

9 Postings, 269 Tage SabrinatqwcaLöschung


Moderation
Zeitpunkt: 26.04.21 11:09
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

27.04.21 13:27

1421 Postings, 4336 Tage logallTrendwende ist da

13.05.21 17:48
1

202 Postings, 1125 Tage Prof.RichLöschung


Moderation
Zeitpunkt: 14.05.21 10:47
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - keine Quelle

 

 

14.05.21 10:18

202 Postings, 1125 Tage Prof.RichLöschung


Moderation
Zeitpunkt: 14.05.21 10:48
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 1 Tag
Kommentar: Marktmanipulation vermutet

 

 

14.05.21 13:23

10244 Postings, 5034 Tage RichyBerlinPhio-News vom 11.05.2021

https://investors.phiopharma.com/news-releases/...-data-asgct-showing
PHIO PHARMACEUTICALS PRESENTS POSITIVE IN VIVO DATA AT ASGCT SHOWING PH-762 SIGNIFICANTLY ENHANCED ANTITUMOR EFFICACY OF HER2-TARGETED CAR-T CELLS
May 11, 2021
 

14.05.21 13:24

10244 Postings, 5034 Tage RichyBerlinPhio Q1-Zahlen von gestern

PHIO PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 13, 2021
https://investors.phiopharma.com/news-releases/...rter-2021-financial
 

04.06.21 18:28

10244 Postings, 5034 Tage RichyBerlinPhio auf der ASCO

https://investors.phiopharma.com/news-releases/...ta-2021-asco-annual
NEWS RELEASE DETAILS
PHIO PHARMACEUTICALS PRESENTS NEW IN VIVO DATA AT THE 2021 ASCO ANNUAL MEETING SHOWING DUAL-TARGETING INTASYL OFFERS INCREASED EFFICACY AND SAFETY POTENTIAL OVER OTHER THERAPEUTIC APPROACHES
Jun 4, 2021
 

16.07.21 18:00

202 Postings, 1125 Tage Prof.RichAkt Projekte

Krebs-Immuntherapie mit Hilfe von mRNA-Impfstoffen! Hört sich spannend an, bei Erfolg ist der zukünftige Aktienkurs vorprogrammiert.  

03.08.21 23:02

10244 Postings, 5034 Tage RichyBerlinPhio lebt

 
Angehängte Grafik:
phio_2021-08-03.png (verkleinert auf 53%) vergrößern
phio_2021-08-03.png

24.08.21 20:31

1421 Postings, 4336 Tage logallwarten auf den Anstieg

31.08.21 23:27

10244 Postings, 5034 Tage RichyBerlinPhio +8% / ESMO-Abstract f. Mitte September

PHIO PHARMACEUTICALS ANNOUNCES UPCOMING DATA PRESENTATION AT THE ESMO VIRTUAL CONGRESS 2021
Aug 31, 2021
MARLBOROUGH, Mass., Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL TM) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.

Details are as follows:
Event: ESMO Virtual Congress 2021
Title: Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors
Authors: Benjamin Cuiffo, et al.
Abstract Number: #4154
Date: September 16-21, 2021  

16.09.21 14:37

10244 Postings, 5034 Tage RichyBerlinPhio-News / Vorbörsl.+17%

Kurs springt vorbörslich... Hoffentlich mal nachhaltig

https://www.nasdaq.com/market-activity/stocks/phio/real-time
 

11.01.22 13:37

10244 Postings, 5034 Tage RichyBerlinPHIO News / +29% derzeit

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
Jan 11, 2022
https://investors.phiopharma.com/news-releases/...-clearance-clinical
MARLBOROUGH, Mass., Jan. 11, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL TM) therapeutic platform, today announced that it has received regulatory clearance to start a clinical trial with its lead product candidate, PH-762. The Company was granted the clinical trial authorization (CTA) by the French National Agency for the Safety of Medicines and Health Products (ANSM - L'Agence nationale de sécurité du médicament et des produits de santé) to proceed with a first-in-human clinical trial for PH-762 to treat patients with melanoma at the Gustave Roussy Institute. The Company expects to dose the first patient in the first quarter of 2022.

"Receiving this clinical trial authorization is an important milestone for Phio as it is the first clinical study of a new generation of immuno-oncology therapeutics based on our INTASYL self-delivering RNAi platform," said Dr. Gerrit Dispersyn, President and CEO of Phio. "This milestone is the first of several planned for this year, as we continue to accelerate our development of our clinical and preclinical product candidates."

PH-762 activates immune cells to better recognize and kill cancer cells. It does so by reducing the expression of PD-1, a clinically validated target for immunotherapy. PD-1 is expressed by T cells and prevents them from killing other cells, including cancer cells. Therefore, reducing PD-1 expression can reduce the ability of cancer cells to evade T cell detection and killing. In preclinical studies, PH-762 has demonstrated robust and durable efficacy in various in vivo tumor models, and importantly has shown that it can elicit an abscopal effect or systemic immune response after local administration.

The Company's first clinical trial with PH-762 will be a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma. There are currently no neoadjuvant treatment options approved for these patients. The study features a dose escalation of PH-762 monotherapy and is designed to allow for a data driven evaluation of the recommended Phase 2 dose..."  

11.01.22 14:31

10244 Postings, 5034 Tage RichyBerlin#448 News

Da fehlte ein wichtiger Satz aus der Überschrift..;

"French regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first quarter of 2022"
 

Seite: 1 | 2 | 3 | 4 |
16 | 17 | 18 | 18   
   Antwort einfügen - nach oben
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln